Aspirin, used at low doses, could reduce the severity of the symptoms and anomalies in the immune system of patients with multiple sclerosis, after their efficacy has been proven in an experiment with mice, according to a study published today in the journal Science Signaling.
According to the research, aspirin administered orally to laboratory mice reduced the severity of the symptoms, slowed down the myelin degradation and inhibited the infiltration of cells in the spinal cord.
The amount of aspirin applied to mice was the equivalent of a dose of the infant version of the medication in adult humans.
Multiple sclerosis is a degenerative disease that affects more than 2.3 million people in the world and whose origin is in the loss of myelin, a protein of the nervous system responsible for transmitting electrical impulses and protecting neurons.
Investigators at the University of Rush (Chicago) discovered an unknown effect of this common drug, commonly used to relieve pain.
With a small amount, aspirin was able to stimulate the production of positive cells for nerve transmission, while slowing down the activity of those malignant cells -Tregg-that attack the nervous system, degrade mileina and are responsible for the imbalance that causes Symptoms of multiple sclerosis.
The scientific team, led by Susanta Mondal, indicated the security that it possesses the active principle of aspirin and its ease of administration, so it could be reused as a supportive therapy for patients with multiple sclerosis and other autoimmune disorders associated with the dysfunction of the same Treg cells. EFE